Université Paris-Sud, AP-HP, Centre de Référence de l'Hypertension Pulmonaire, Service de Pneumologie, Département Hospitalo-Universitaire (DHU) Thorax Innovation (TORINO), Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
INSERM UMR_S999, LabEx LERMIT, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management.Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup "pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers", due to the specific prognostic and management of these patients, and a subgroup "PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement", due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.
自 1973 年第一届世界肺动脉高压研讨会(WSPH)以来,肺动脉高压(PH)一直被任意定义为右心导管测量时静息状态下平均肺动脉压(mPAP)≥25mmHg。最近来自正常受试者的数据显示,正常 mPAP 为 14.0±3.3mmHg。该平均值的两个标准差以上表明 mPAP >20mmHg,高于正常上限(第 97.5 个百分位数以上)。该定义不再是任意的,而是基于科学方法。然而,mPAP 的这种异常升高不足以定义肺血管疾病,因为它可能是由于心输出量或肺动脉楔压增加引起的。因此,第六届 WSPH 工作组提议在所有与 mPAP >20mmHg 相关的前毛细血管 PH 的定义中纳入肺血管阻力≥3 伍德单位。需要进行前瞻性试验来确定这一 PH 人群是否可能受益于特定的管理。关于临床分类,主要工作组的变更包括将“长期对钙通道阻滞剂有反应的肺动脉高压(PAH)”亚组纳入第 1 组,这是由于这些患者的特定预后和管理,以及“有明显静脉/毛细血管(肺静脉闭塞病/肺毛细血管血管瘤病)受累特征的 PAH”亚组,因为有证据表明 PAH 中动脉、毛细血管和静脉受累之间存在连续性。